uniQure sharpens gene therapy focus as AMT-130 targets 2026 FDA filing

uniQure is reshaping its gene therapy strategy around a faster regulatory path for AMT-130, its Huntington's disease candidate, while narrowing its operating model to pure research and development.

uniQure's AMT-130 gene therapy for Huntington's disease could reach the FDA by the third quarter of 2026 after the agency accepted three-year Phase I/II data as the primary basis for an accelerated approval filing, the company said after a recent Type B meeting.

"The FDA's feedback gives us a clearer regulatory path for AMT-130," Matt Kapusta, chief executive officer of uniQure, said. The agency indicated that three-year data from the Phase I/II study could support a biologics license application seeking accelerated approval, though alignment on the confirmatory trial design remains outstanding.

The company reported a cash runway extending into the second half of 2029, providing financial flexibility through the regulatory process. Beyond Huntington's, uniQure's pipeline includes AMT-260 for refractory mesial temporal lobe epilepsy, where three of six patients in the first low-dose cohort achieved 79 percent to 100 percent reductions in disabling seizures during months four through six. AMT-191 for Fabry disease showed sustained increases in alpha-galactosidase A enzyme activity and stable Lyso-Gb3 levels, with all 11 dosed patients having discontinued enzyme replacement therapy as of February 18.

Regulatory Path Takes Center Stage

AMT-130 has received Regenerative Medicine Advanced Therapy, Breakthrough Therapy and Fast Track designations from the FDA, reflecting the high unmet need in Huntington's disease, a condition with no approved disease-modifying treatments. The therapy uses uniQure's miQURE gene-silencing platform, employing a microRNA designed to silence the huntingtin gene and the potentially toxic exon 1 protein fragment.

The FDA has favored a concurrent standard-of-care control group rather than a sham-controlled trial for the confirmatory study, a detail that shapes the design costs and timeline. uniQure plans to complete regulatory alignment before its targeted third-quarter 2026 submission.

PTC Therapeutics, whose PTC518 program has received Fast Track designation for Huntington's disease, and Wave Life Sciences give investors additional reference points in the space. Their presence underscores the competitive landscape uniQure faces as it advances AMT-130 through the regulatory process.

A Leaner Operating Model

uniQure is also simplifying its business structure. After selling its commercial manufacturing business to Genezen in 2024, the company moved in 2026 to transfer HEMGENIX manufacturing responsibilities directly to Genezen. The remaining HEMGENIX supply and minimum purchase commitments are expected to end after delivery of specified batches, with no impact on future royalties or milestone payments from CSL Behring.

The result is a more focused research-and-development organization. Sarepta Therapeutics, which has a rare neuromuscular portfolio including gene therapy and exon-skipping treatments in Duchenne muscular dystrophy, shows why execution remains central for genetic medicine companies.

What This Means for Investors

QURE shares have rallied on the clearer regulatory outlook, but the stock's valuation now reflects a higher probability of AMT-130 success. The confirmatory trial design discussions with the FDA will be the next major catalyst, and any delays or design complications could pressure the stock. The pipeline beyond Huntington's — AMT-260 in epilepsy and AMT-191 in Fabry disease — provides optionality but remains early-stage. With cash runway through 2029, uniQure has time to execute, but the next 12 months of regulatory alignment will determine whether the current valuation is justified.

This article is for informational purposes only and does not constitute investment advice.